A comparison of estimated drug costs of potentially inappropriate medications between older patients receiving nurse home visit services and patients receiving pharmacist home visit services: a cross-sectional and propensity score analysis by Hamano Jun et al.
A comparison of estimated drug costs of
potentially inappropriate medications between
older patients receiving nurse home visit
services and patients receiving pharmacist
home visit services: a cross-sectional and
propensity score analysis
著者 Hamano Jun, Ozone Sachiko, Tokuda Yasuharu
journal or
publication title
BMC health services research
volume 15
page range 73
year 2015-02
権利 (C) 2015 Hamano et al.; licensee BioMed
Central. This is an Open Access article
distributed under the terms of the Creative
Commons Attribution License
(http://creativecommons.org/licenses/by/4.0),
which permits unrestricted use, distribution,
and reproduction in any medium, provided the
original work is properly credited. The
Creative Commons Public Domain Dedication
waiver
(http://creativecommons.org/publicdomain/zero/
1.0/) applies to the data made available in
this article, unless otherwise stated.
URL http://hdl.handle.net/2241/00124375
doi: 10.1186/s12913-015-0732-4
Creative Commons : 表示
http://creativecommons.org/licenses/by/3.0/deed.ja
Hamano et al. BMC Health Services Research  (2015) 15:73 
DOI 10.1186/s12913-015-0732-4RESEARCH ARTICLE Open AccessA comparison of estimated drug costs of
potentially inappropriate medications between
older patients receiving nurse home visit services
and patients receiving pharmacist home visit
services: a cross-sectional and propensity
score analysis
Jun Hamano1*, Sachiko Ozone2† and Yasuharu Tokuda3†Abstract
Background: There have been no multicenter studies that estimated the relations of either nurse or pharmacist
home visit program to drug costs of potentially inappropriate medications (PIMs). This study aimed to establish
whether patients who used nurse or pharmacist home visit programs (nurse or pharmacist program) had lower
drug costs of PIMs than those who did not use nurse or pharmacist programs for older patients living at home.
Methods: This cross-sectional study was conducted in home care settings in Japan, involving 430 patients aged 65
or older, of whom 276 were female. All received regular home visits from five clinics between May and December
2013. After the PIMs were identified with the Screening Tool of Older Persons' potentially inappropriate Prescriptions
(STOPP) criteria, we estimated the drug costs based on actual pharmaceutical prices and measured against who
using nurse or pharmacist programs after a propensity score weighted adjustment.
Results: Patients who used nurse programs had lower drug cost of PIMs than those who did not use, but it was
not significantly different (5.9 ± 13.1 vs 7.1 ± 13.9 USD per month, P = 0.199). The cost of PIMs for patients who
used pharmacist programs also had no difference. (7.2 ± 14.5 vs 5.5 ± 11.5 USD per month, P = 0.06). In the patient
groups who used nurse programs, patients who also used pharmacist programs had significantly higher costs of
PIMs than those who used only nurse programs (5.5 ± 13.9 vs 2.5 ± 6.0 USD per month, P = 0.006). In patients
group who did not use pharmacist programs, patients who only used nurse programs had significantly lower costs
of PIMs than those who did not use nurse programs (3.6 ± 7.7 vs 5.8 ± 12.7 USD per month, P = 0.022).
Conclusions: Patients who used nurse program have a trend towards lower drug costs of PIMs than those who
used nurse and pharmacist program or pharmacist program alone. Although this study tried to adjust the potential
confounders as possible as we could by using propensity score analysis, further studies are needed to confirm
our results.* Correspondence: junhamano@md.tsukuba.ac.jp
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Prescription medications are an essential component of
the care of older patients. Although some medications
can cure and prevent disease, inappropriate medication
may have detrimental effects. Potentially inappropriate
medications (PIMs) have been defined as medications
that carry more risks than benefits, those with clinically
significant drug–drug or drug–disease interactions [1,2].
Several studies have shown that PIMs among older pa-
tients are correlated with increased adverse drug reactions
(ADRs) [3-6], health care utilization [7-9], death [10,11],
poor adherence [12,13] and greater economic burden
[7,14,15]. The cost of potentially inappropriate medica-
tions is estimated to be high [16-18], and this has become
an important public health issue worldwide [2]. PIMs
among older home care patients are common [19], and an
important issue in developed countries with an aging
population, such as Japan, where the number of older
home care patients is predicted to increase rapidly in
the future.
Several tools are used to detect PIMs in older people
[20], such as the Beers’ criteria [21], the Screening Tool
of Older Persons' potentially inappropriate Prescriptions
(STOPP) [22,23] and the Improved Prescribing in the
Elderly Tool (IPET) [24]. Recent studies showed that the
STOPP criteria have high sensitivity for detecting poten-
tial drug-related problems [25] and are more sensitive in
detecting PIMs than the Beers’ criteria [26].
Several intervention studies have revealed that a multi-
disciplinary approach for older patients could reduce the
number of patients with PIMs [27,28] and detect a high
proportion of clinically relevant DRPs [29,30]. One pre-
vious study conducted in home care settings revealed
that a medication review by a community pharmacist
could reduce the number of medications, but it was not
clear about the relations of pharmacist intervention to
drug costs of PIMs [31]. As far as we know, there has
been no multicenter study that estimated the relations of
either nurse or pharmacist home visit program to drug
cost of PIMs identified by the STOPP criteria for older pa-
tients in home care settings. This study aimed to validate
whether the patients who using either nurse or pharmacist
home visit programs had lower drug costs of potentially
inappropriate medication based on actual pharmaceutical
prices than who not using nurse or pharmacist home visit
programs for older patients in a home care setting.
Methods
This cross-sectional study was conducted at five clinics
in Japan between May and December 2013. These clinics
provide primary care by ambulatory service and home
visit services for community residents, and each clinics
collaborate with home visit nurses and pharmacists de-
pending on the situation. None of these doctors werefamiliar with the STOPP criteria at the starting time of
study. In general, nurse home visit programs in Japan
provide hands-on care at home, for example to help
bathing, to promote physical activity and to coordinate
living environment. Pharmacist home visit programs in
Japan usually consult with patient regarding expected or
unexpected effects of drugs and monitor the adherence
of prescription at home. The frequency of their home
visit depended on patients’ conditions and needs for
care, typically twice or four times a month by nurse and
a once or twice a month by pharmacist.
Although, the primary care doctors responsible for
care of individual patients typically recommend using
the home visit program and patients or their family
could decide to use or not, the patients and their family
could use the programs whenever they requested.
The study was approved by the ethics committee of the
Mito Kyodo General Hospital and was conducted accord-
ing to the principles expressed in the Declaration of
Helsinki. We included all patients who were 65 years or
older and who satisfied our inclusion criteria, which were:
1) patients received home visit services regularly by their
doctors at least twice a month for over a month, and
2) patients had been regularly prescribed medications
by the clinic, excluding topical drugs.
We used medical records to collect patients' back-
ground information, which included age, sex, estimated
glomerular filtration rate (eGFR: ml/min), serum albu-
min (mg/dl), availability of overview of ambulation and
drug use, underlying medical conditions, whether they
lived with or without family, and whether they used a
home visit nurse or pharmacist.
We had collected the copies of prescription contents
by single monthly basis during the survey period which
was sent from each clinic and confirmed the medication.
We defined PIMs as having occurred when at least
one of the original STOPP criteria was met (Table 1).
We calculated the total monthly drug cost of all patients
and the monthly drug cost of PIMs. We estimated the
drug cost based on actual pharmaceutical prices listed
by the regulatory committee at the Ministry of Health,
Labour and Welfare, Japanese government.
Statistical methods
We used Student’s t test for continuous variables and
Pearson’s χ2 test or Fisher’s exact test for categorical vari-
ables to test for significant associations between patients’
baseline characteristics and the use of the home visit nurse
or pharmacist. We used a propensity score weighting
technique to assess the association between the monthly
drug cost of PIMs and the use of the home visit nurse or
pharmacist and to adjust for confounding factors.
Table 1 STOPP screening criteria [22]
STOPP criteria
A. Cardiovascular system
1 Digoxin at a long-term dose >125 mg/d with impaired renal function
2 Loop diuretic as first-line monotherapy for hypertension or for dependent ankle edema only
3 Thiazide diuretic with a history of gout
4 Noncardioselective b-blocker with chronic obstructive pulmonary disease
5 b-blocker in combination with verapamil
6 Use of diltiazem or verapamil with New York Heart Association class 3 or 4 heart failure
7 Calcium-channel blockers with chronic constipation
8
Use of aspirin and warfarin in combination without histamine H2 receptor antagonist
(except cimetidine) or proton pump inhibitor
9 Dipyridamole as monotherapy for cardiovascular secondary prevention
10 Aspirin with no history of coronary, cerebral or peripheral vascular symptoms
or occlusive arterial event or with a past history of peptic ulcer disease
without histamine H2 receptor antagonist or proton pumpinhibitor or at dose >150 mg/d
or to treat dizziness not clearly attributed to cerebrovascular disease
11 Warfarin for first, uncomplicated deep venous thrombosis for longer than 6-month duration
or for first, uncomplicated pulmonary embolus for longer than 12-month duration
12 Aspirin, clopidogrel, dipyridamole, or warfarin with concurrent bleeding disorder
B. CNS and psychotropic drugs
1 Tricyclic antidepressants with dementia or with glaucoma or with cardiac conductive abnormalities
or with constipation or with prostatism or prior history of urinary retention or with an opiate
or calcium-channel blocker
2 Long-term (>3 month) use of long-acting benzodiazepines, and with long-acting metabolites
3 Long-term (>1 month) neuroleptics as long-term hypnotics or in those with parkinsonism
4 Phenothiazines in patients with epilepsy
5 Anticholinergics to treat extrapyramidal side effects of neuroleptic medications
6 Selective serotonin reuptake inhibitors with a history of clinically significant hyponatremia
(noniatrogenic hyponatremia <130 mmol/L within the previous 2 months)
7 Prolonged use (>1 week) of first-generation antihistamines
C. Gastrointestinal system
1 Diphenoxylate, loperamide or codeine phosphate for treatment of diarrhea of unknown cause
or severe infective gastroenteritis
2 Prochlorperazine or metoclopramide with parkinsonism
3 Proton pump inhibitors for peptic ulcer disease at full therapeutic dosage for >8 weeks
4 Anticholinergic antispasmodic drugs with chronic constipation
D. Respiratory system
1 Theophylline as monotherapy for chronic obstructive pulmonary disease
2 Systemic corticosteroids instead of inhaled corticosteroids for maintenance therapy
in moderate-to-severe chronic obstructive pulmonary disease
3 Nebulized ipratropium with glaucoma
E. Musculoskeletal system
1 NSAID with history of peptic ulcer disease or gastrointestinal bleeding, unless with concurrent
histamine H2 receptor antagonist, proton pump inhibitor, or misoprostol
2 NSAID with moderate-to-severe hypertension or with heart failure
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Table 1 STOPP screening criteria [22] (Continued)
3 Long-term use of NSAID (>3 months) for relief of mild joint pain in osteoarthritis
4 Warfarin and NSAID together
5 NSAID with chronic renal failure
6 Long-term corticosteroids (>3 months) as monotherapy for rheumatoid arthritis
or osteoarthritis
7 Long-term NSAID or colchicine for chronic treatment of gout where there is
no contraindication to allopurinol
F. Urogenital system
1 Bladder antimuscarinic drugs with dementia or with chronic glaucoma
or with chronic constipation or with chronic prostatism
2 a-blockers in males with frequent incontinence
3 a-blockers with long-term urinary catheter in situ (>2 months)
G. Endocrine system
1 Glibenclamide or chlorpropamide with type 2 diabetes mellitus
2 b-blockers in those with diabetes mellitus and frequent hypoglycemic episodes
3 Estrogens with a history of breast cancer or venous thromboembolism
4 Estrogens without progestogen in patients with intact uterus
H. Drugs that adversely affect those prone to falls
(at least 1 fall in past 3 months)
1 Benzodiazepines
2 Neuroleptic drugs
3 First-generation antihistamines
4 Vasodilator drugs known to cause hypotension in those with persistent postural hypotension
5 Long-term opiates in those with recurrent falls
I. Analgesic drugs
1 Use of long-term powerful opiates as first-line therapy for mild-to-moderate pain
2 Regular opiates for more than 2 weeks in those with chronic constipation
without concurrent use of laxatives
3 Long-term opiates in those with dementia unless indicated for palliative care
or management of moderate-to-severe chronic pain syndrome
J. Duplicate drug classes
1 Any regular duplicate drug class prescription, such as two concurrent opiates, NSAIDs,
serotonin-specific reuptake inhibitors, loop diuretics, and ACE inhibitors
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variables as those that 1) were hypothesized to be
strongly associated with the use of the home visit nurse
or pharmacist and PIMs, and 2) were hypothesized
to be associated with PIMs, and excluded those that
1) were associated with other aspects as well as the use
of the home visit nurse and pharmacist, 2) were af-
fected by the use of the home visit nurse or pharma-
cist, 3) perfectly predict the use of the home visit nurse
and pharmacist [32].
We then used logistic regression to calculate the pro-
pensity score, categorizing the patient age into three
groups: 65–74, 75–84, and >85 years.The logistic regression model for the propensity score
for the use of the nurse home visit programs (PS for
nurse) included age category, sex, availability of overview
on ambulation and drug use, whether they lived with or
without family, the use of the home visit pharmacist, num-
ber of prescriptions and underlying medical conditions
(constipation, hypertension, dementia, cerebral infarction/
transient ischemic attack, diabetes mellitus, atrial fibril-
lation, progressive malignancy, hyperuricemia/gout,
heart failure, dyslipidemia, Parkinson’s Disease/Parkinson’s
syndrome, osteoporosis, chronic obstructive pulmonary
disease, peripheral artery occlusive disease, cerebral/sub-
arachnoid hemorrhage, osteoarthritis) as variables.
Table 2 Patient background (n = 430)
Before propensity score weighted adjustment After propensity score weighted adjustment
All patients Using nurse home visit programs Using pharmacisthome visit programs
Using nurse home visit
programs (weighted by
PS for nurse)
Using pharmacist home
visit programs (weighted
by PS for pharmacist)
(n = 430);
n (%)
Patients who
used nurse
home visit
programs
(n = 203);
n (%)
Patients who
did not used
nurse home
visit programs
(n = 227);
n (%)
P-
value
Patients
who used
pharmacist
home visit
programs
(n = 182);
n (%)
Patients who
did not used
pharmacist
home visit
programs
(n = 248);
n (%)
P-
value
Patients who
used nurse
home visit
programs (%)
Patients
who did
not used
nurse home
visit programs
(%)
P-
value
Patients
who used
pharmacist
home visit
programs (%)
Patients who
did not used
pharmacist
home visit
programs (%)
P-
value
Gender 0.013 0.073 0.924 0.950
Male 154 (35.8%) 85 (41.9%) 69 (30.4%) 74 (40.7%) 80 (32.3%) (34.3%) (34.0%) (35.6%) (35.4%)
Female
276 (64.2%) 118 (58.1%) 158 (69.6%)
108
(59.3%)
168 (67.7%) (65.7%) (66.0%) (64.4%) (64.6%)
Mean age (years ±
standard deviation)
85.0 ± 8.3 84.3 ± 8.6 85.7 ± 8.0 0.07 84.7 ± 8.1 85.2 ± 8.4 0.523 85.5 ± 8.5 84.9 ± 8.1 0.298 85.3 ± 8.3 85.0 ± 8.2 0.575
Age (years) 0.004 0.177 0.909 0.976
65-74 55 (12.8%) 29 (14.3%) 26 (11.5%) 22 (12.1%) 33 (13.3%) (12.0%) (12.1%) (12.9%) (12.4%)
75-84 126 (29.3%) 73 (36.0%) 53 (23.3%) 62 (34.1%) 64 (25.8%) (30.6%) (31.9%) (28.8%) (29.0%)
≥85 249 (57.9%) 101 (49.8%) 148 (65.2%) 98 (53.8%) 151 (60.9%) (56.0%) (56.0%) (58.3%) (58.5%)
Independent
ambulation
199 (46.3%) 71 (35.0%) 128 (56.4%) <0.001 91 (50.0%) 108 (43.5%) 0.185 (45.3%) (45.6%) 0.925 (45.9%) (46.1%) 0.934
Independent
drug overview
115 (26.7%) 44 (21.7%) 71 (31.3%) 0.025 54 (29.7%) 61 (24.6%) 0.24 (22.8%) (24.8%) 0.482 (27.4%) (26.7%) 0.812
Living with family
381 (88.6%) 190 (93.6%) 191 (84.1%) 0.002
155
(85.2%)
226 (91.1%) 0.054 (87.3%) (88.4%) 0.626 (88.7%) (88.1%) 0.774
Using home visit
programs by nurse
203 (47.2%) - - - 78 (42.9%) 125 (50.4%) 0.121 - - - (47.7%) (47.1%) 0.855
Using home visit
programs by
pharmacist
182 (42.3%) 78 (38.4%) 104 (45.8%) 0.121 - - - (41.5%) (42.2%) 0.844 - - -
Underlying medical
conditions
Constipation
243 (56.5%) 113 (55.7%) 130 (57.3%) 0.738
115
(63.2%)
128 (51.6%) 0.017 59.6% 59.4% 0.955 55.4% 56.2% 0.818
Hypertension
228 (53.0%) 84 (41.4%) 144 (63.4%) <0.001
101
(55.5%)
127 (51.2%) 0.379 49.5% 51.8% 0.513 52.8% 53.2% 0.907
Dementia 218 (50.7%) 87 (42.9%) 131 (57.7%) 0.002 89 (48.9%) 129 (52.0%) 0.523 52.5% 54.2% 0.601 50.9% 51.5% 0.860
104 (24.2%) 45 (22.2%) 59 (26.0%) 0.355 44 (24.2%) 60 (24.2%) 0.997 26.8% 24.5% 0.456 24.7% 25.1% 0.906
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Table 2 Patient background (n = 430) (Continued)
Cerebral infarction/
transient ischemic
attack
Osteoporosis 95 (22.1%) 38 (18.7%) 57 (25.1%) 0.111 47 (25.8%) 48 (19.4%) 0.11 26.0% 22.9% 0.299 22.1% 22.5% 0.898
Diabetes mellitus 82 (19.1%) 33 (16.3%) 49 (21.6%) 0.16 43 (23.6%) 39 (15.7%) 0.039 20.2% 19.1% 0.691 19.2% 19.7% 0.852
Coronary artery
disease
59 (13.7%) 27 (13.3%) 32 (14.1%) 0.811 28 (15.4%) 31 (12.5%) 0.39 13.3% 15.3% 0.410 11.8% 13.1% 0.544
Atrial fibrillation 55 (12.8)% 29 (14.3%) 26 (11.5%) 0.38 27 (14.8%) 28 (11.3%) 0.277 12.9% 12.3% 0.776 12.7% 12.2% 0.816
Dyslipidemia 51 (11.9%) 17 (8.4%) 34 (15.0%) 0.034 27 (14.8%) 24 (9.7%) 0.102 9.9% 11.8% 0.358 12.2% 12.6% 0.847
Benign prostatic
hypertrophy
47 (10.9%) 24 (11.8%) 23 (10.1%) 0.575 22 (12.1%) 25 (10.1%) 0.51 10.1% 11.6% 0.485 9.9% 10.8% 0.685
Progressive
malignancy
34 (7.9%) 23 (11.3%) 11 (4.8%) 0.013 14 (7.7%) 20 (8.1%) 0.888 7.5% 7.1% 0.807 7.2% 7.7% 0.751
Hyperuricemia/gout 32 (7.4%) 9 (4.4%) 23 (10.1%) 0.025 19 (10.4%) 13 (5.2%) 0.042 9.2% 7.8% 0.473 8.1% 8.2% 0.951
Heart failure 30 (7.0%) 17 (8.4%) 13 (5.7%) 0.282 14 (7.7%) 16 (6.5%) 0.618 5.0% 7.3% 0.163 6.2% 5.9% 0.815
Parkinson's Disease/
Parkinson's syndrome
28 (6.5%) 14 (6.9%) 14 (6.2%) 0.76 13 (7.1%) 15 (6.0%) 0.649 7.5% 7.8% 0.866 6.2% 6.6% 0.840
Chronic obstructive
pulmonary disease
27 (6.3%) 19 (9.4%) 8 (3.5%) 0.013 17 (9.3%) 10 (4.0%) 0.025 5.9% 3.8% 0.156 6.0% 5.2% 0.592
Peripheral artery occlusive
disease
27 (6.3%) 7 (3.4%) 20 (8.8%) 0.022 16 (8.8%) 11 (4.4%) 0.066 4.0% 5.7% 0.253 6.0% 5.6% 0.816
Cerebral/
subarachnoid hemorrhage
26 (6.0%) 11 (5.4%) 15 (6.6%) 0.606 17 (9.3%) 9 (3.6%) 0.014 5.2% 6.4% 0.452 6.0% 6.3% 0.846
Osteoarthritis 21 (4.9%) 6 (3.0%) 15 (6.6%) 0.079 9 (4.9%) 12 (4.8%) 0.96 5.6% 5.0% 0.658 5.1% 4.9% 0.919
Number of
prescriptions
(mean ± standard
deviation)
6.1 ± 3.0 6.3 ± 3.0 5.8 ± 3.0 0.065 6.6 ± 3.1 5.6 ± 2.8 <0.001 6.2 ± 3.0 6.0 ± 3.1 0.427 5.9 ± 3.0 6.0 ± 3.0 0.879
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Table 3 Most frequent prescriptions resulting in PIMs
Prescription (n = 430); n (%)
1 Calcium-channel blockers with chronic constipation 74 (17.2%)
2 Long-term use of NSAID (>3 months) for relief of mild joint pain in osteoarthritis 16 (3.7%)
3 Long-term (>1 month) use of long-acting benzodiazepines, and with long-acting metabolites 15 (3.5%)
4 NSAID with moderate-to-severe hypertension or with heart failure 14 (3.3%)
5 Loop diuretic as first-line monotherapy for hypertension or for dependent ankle edema only 13 (3.0%)
6
Any regular duplicate drug class prescription, such as two concurrent opiates, NSAIDs,
serotonin-specific reuptake inhibitors, loop diuretics, and ACE inhibitors
11 (2.6%)
7 Benzodiazepines for patients who have had at least 1 fall in the past 3 months 10 (2.3%)
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the pharmacist home visit programs (PS for pharmacist)
using a logistic regression model that included the same
variables as for the nurse home visit programs, except
that use of the pharmacist home visit programs was
changed to use of the nurse home visit program.
To examine the association between the monthly drug
cost of PIMs and use of the nurse or pharmacist home
visit programs, we used a multivariate logistic regression
analysis and included use of the home visit programs
with the propensity score as variables. All analyses were
conducted using SPSS-J (ver. 22.0; IBM, Tokyo, Japan).
Results
Demography
We included 430 patients in this study, of whom 276
were female. Table 2 shows detailed patient background
information. The mean patient age was 85.0 ± 8.3 years.
The main underlying medical conditions were constipa-
tion in 243 patients (56.5%), hypertension in 228 pa-
tients (53.0%), and dementia in 218 patients (50.7%).
Nearly half, 203 patients (47.2%), had used the nurse
home visit programs and 182 (42.3%) had used the
pharmacist home visit programs. Almost one fifth, 78
patients (18.1%), had used both nurse and pharmacist
home visit programs (Table 2). Over one quarter, 123
patients (28.6%), had not used either program.Table 4 The cost of PIMs in patients group who used nurse h
(Total cost of PIMs per patient per month in USD)
Using pharmacist home visit pr
n
Patients who used
pharmacist home visit
programs (n = 182)
Patie
use p
visit
All patients† 430 7.2 ± 14.5 5.5 ±
Patients who used nurse home
visit programs†
203 5.5 ± 13.9 2.5 ±
Patients who did not use nurse
home visit programs†
227 8.7 ± 15.7 8.1 ±
†drug cost (USD) ± standard deviation.Propensity score weighting successfully balanced the ob-
served differences in patient background and the use of
the two home visit programs (Table 2).
Specific prescriptions of PIMs
By the STOPP criteria, 34.0% of the study population re-
ceived at least one PIM. We found that the most common
prescriptions resulting in PIMs were (a) calcium-channel
blockers in patients with chronic constipation (74 patients,
17.2%), (b) long-term use of NSAIDs for relief of mild joint
pain in osteoarthritis (16 patients, 3.7%), (c) long-term use
of long-acting benzodiazepines (15 patients, 3.5%), and (d)
NSAIDs in patients with moderate-to-severe hypertension
or with heart failure (14 patients, 3.3%) (Table 3).
The cost of PIMs after propensity score weighted
adjustment
After propensity score weighted adjustment, we com-
pared the total cost of PIMs per patient per month in
USD (100 Japanese Yen = 1 USD) in all patients and each
subgroup (Table 4, 5). Although it was not significantly dif-
ferent, patients who used the pharmacist home visit pro-
grams had higher drug costs of PIMs (7.2 ± 14.5 vs 5.5 ±
11.5 USD per month, P = 0.06) (Table 4). On the other
hand, the drug cost of PIMs for patients who used the
nurse home visit programs was lower than those who did
not use, but it was not significantly different (5.9 ± 13.1 vsome visit or not
ograms (weighted by PS for pharmacist)
nts who did not
harmacist home
programs (n = 248)
Difference between
two groups 95% CI P-value
11.5 −1.7 −3.5 - 0.07 0.06
6.0 −2.9 −5.0 - -0.83 0.006
14.2 −0.66 −3.4 - 2.1 0.64
Table 5 The cost of PIMs in patients group who used pharmacist home visit or not
(Total cost of PIMs per patient per month in USD)
Using nurse home visit programs (weighted by PS for nurse)
n
Patients who used
nurse home visit
programs (n = 203)
Patients who did not
use nurse home visit
programs (n = 227)
Difference
between
two groups
95% CI P-value
All patients† 430 5.9 ± 13.1 7.1 ± 13.9 1.2 −0.63 - 3.0 0.199
Patients who used pharmacist home visit programs† 182 9.1 ± 17.8 8.8 ± 15.3 −0.22 −3.7 - 3.2 0.898
Patients who did not use pharmacist home visit programs† 248 3.6 ± 7.7 5.8 ± 12.7 2.2 0.31 - 4.0 0.022
†drug cost (USD) ± standard deviation.
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tient groups who used nurse home visiting programs, pa-
tients who also used pharmacist home visiting programs
had significantly higher costs of PIMs than those who
used only nurse home visit programs (5.5 ± 13.9 vs 2.5
± 6.0 USD per month, P = 0.006) (Table 4). In the pa-
tient groups who did not use pharmacist home visit
programs, patients who only used nurse home visit pro-
grams had significantly lower costs of PIMs than those
who did not use nurse home visit programs (3.6 ± 7.7 vs
5.8 ± 12.7 USD per month, P = 0.022) (Table 5).Discussion
As far as we know, this is the first study to estimate the
relations of nurse and pharmacist home visit program to
drug costs of PIMs identified by the STOPP criteria for
older patients in home care settings.
The important finding of this study is that those who
used nurse home visit program have a trend towards
lower drug costs of PIMs than those who used nurse
and pharmacist home visit program or pharmacist home
visit program alone.
There are several explanations about this finding. First,
pharmacist home visit programs tend to involve patients
with complicated conditions and PIMs might have been
actually appropriate in these circumstances.
Second, although pharmacists understood the concept
and meaning of PIMs, pharmacist home visit programs
may be more difficult to help for improving the prescrip-
tion than nurse home visit programs. This hypothesis is
based on the situation of pharmacist home visit pro-
grams in Japan. In general, pharmacist home visit pro-
grams in Japan are expected to encourage to keep the
drug adherence and to identify the symptoms as possible
drug side effects. On the other hand, pharmacists of
home visit programs usually did not receive the details
of patients’ medical history from doctors and were not
expected to give advice to doctors about prescription, al-
though nurse home visit program usually is provided
about the details of patients’ medical history and oftenbe required to give advice to their patients about pre-
scriptions from doctors in Japan.
Third, there might have been other unidentified con-
founding variables that might affect the effectiveness of
home visit programs to the drug costs of PIMs. We need to
conduct further research to reveal factors, which may affect
the drug costs of PIMs in home care setting prospectively.
This study had four main limitations. First, we might
not be able to assess the all of potential confounders that
might affect the drug cost of PIMs in home care setting
and the effectiveness of home visit program.
Second, because of its cross-sectional nature, there
might have been several potential confounders, we could
assess in this study, which could affect the drug costs of
PIMs and the effectiveness of home visit program. We
performed our analysis to adjust the potential confounders
as possible as we could by using propensity scores.
Third, our study sample may not be representative of
older home care patients, because it was carried out at
only a few institutions in Japan. Further work is needed
to carry out a larger study with the greater number of
institutions in Japan and other countries.
Finally, we cannot draw conclusions about the effect-
iveness of nurse and pharmacist home visit program to
drug cost of PIMs, because our study was not an inter-
vention study. We would need to carry out further re-
search, including a longitudinal intervention study, to
assess the effectiveness of nurse and pharmacist home
visit program to drug cost of PIMs.
Conclusion
In conclusion, those who used nurse home visit program
have a trend towards lower drug costs of PIMs than those
who used nurse and pharmacist home visit program or
pharmacist home visit program alone. Although, this study
aimed to adjust the potential confounders as possible as we
could by using propensity score analysis, caution may be
needed about interpretation of this study. Further research
is needed to consider all of potential confounders associ-
ated with the drug costs of PIMs in home care setting and
using home visit program.
Hamano et al. BMC Health Services Research  (2015) 15:73 Page 9 of 9Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JH and YT participated in the design of the study and helped to perform the
statistical analysis and draft the manuscript. SO contributed to interpretation
of the data and manuscript revisions. All authors read and approved the
final manuscript.
Acknowledgments
Research funds for this study were provided by a Clinical Research Grant
from St. Luke’s Life Science Institute. We would also like to express our
gratitude to Kazuhiro Hisajima, MD, Shohei Kawagoe, MD, Hiroyuki Beniya,
MD, and Yasuyuki Arai, MD for data collection.
Author details
1Division of Clinical Medicine, Faculty of Medicine, University of Tsukuba,
Tsukuba, Japan. 2Primary Care and Medical Education, Graduate School of
Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan.
3Japan Community Healthcare Organization, 3-22-12 Takanawa, Tokyo, Japan.
Received: 29 September 2014 Accepted: 8 February 2015
References
1. Gallagher P, O’Mahony D. Inappropriate prescribing in older people. Rev
Clin Gerontol. 2008;18(01):65.
2. Spinewine A, Schmader KE, Barber N, Hughes C, Lapane KL, Swine C, et al.
Appropriate prescribing in elderly people: how well can it be measured and
optimised? Lancet. 2007;370(9582):173–84.
3. Gallagher PF, Barry PJ, Ryan C, Hartigan I, O’Mahony D. Inappropriate
prescribing in an acutely ill population of elderly patients as determined by
Beers’ Criteria. Age Ageing. 2008;37(1):96–101.
4. Chang C-M, Liu P-YY, Yang Y-HK, Yang Y-C, Wu C-F, Lu F-H. Use of the Beers
criteria to predict adverse drug reactions among first-visit elderly
outpatients. Pharmacotherapy. 2005;25(6):831–8.
5. Routledge PA, O’Mahony MS, Woodhouse KW. Adverse drug reactions in
elderly patients. Br J Clin Pharmacol. 2004;57(2):121–6.
6. Lindley CM, Tully MP, Paramsothy V, Tallis RC. Inappropriate medication is a
major cause of adverse drug reactions in elderly patients. Age Ageing.
1992;21(4):294–300.
7. Fick DM, Mion LC, Beers MH, Waller JL. Health outcomes associated with
potentially inappropriate medication use in older adults. Res Nurs Health.
2008;31(1):42–51.
8. Passarelli MCG, Jacob-Filho W, Figueras A. Adverse drug reactions in an
elderly hospitalised population: inappropriate prescription is a leading cause.
Drugs Aging. 2005;22(9):767–77.
9. Schneeweiss S, Hasford J, Göttler M, Hoffmann A, Riethling A-K, Avorn J.
Admissions caused by adverse drug events to internal medicine and emergency
departments in hospitals: a longitudinal population-based study. Eur Jj Clin
Pharmacol. 2002;58(4):285–91.
10. Klarin I, Wimo A, Fastbom J. The association of inappropriate drug use with
hospitalisation and mortality: a population-based study of the very old.
Drugs Aging. 2005;22(1):69–82.
11. Ebbesen J, Buajordet I, Erikssen J, Brørs O, Hilberg T, Svaar H, et al. Drug-
related deaths in a department of internal medicine. Arch Intern Med.
2001;161(19):2317–23.
12. Kripalani S, Henderson LE, Jacobson TA, Vaccarino V. Medication use among
inner-city patients after hospital discharge: patient-reported barriers and
solutions. Mayo Clin Proc. 2008;83(5):529–35.
13. Mansur N, Weiss A, Beloosesky Y. Is there an association between
inappropriate prescription drug use and adherence in discharged elderly
patients? Ann Pharmacother. 2009;43(2):177–84.
14. Fick DM, Waller JL, Maclean JR, Heuvel RV, Tadlock JG, Gottlieb M, et al.
Potentially inappropriate medication use in a Medicare managed care
population: Association with higher costs and utilization. J Manag Care
Pharm. 2001;7(5):407–13.
15. Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, Petersen LA, et al. The costs
of adverse drug events in hospitalized patients adverse drug events
prevention study group. JAMA. 1997;277(4):307–11.16. Al-Omar HA, Al-Sultan MS, Abu-Auda HS. Prescribing of potentially inappropriate
medications among the elderly population in an ambulatory care setting in a
Saudi military hospital: trend and cost. Geriatr Gerontol Int. 2013;13(3):616–21.
17. Cahir C, Fahey T, Teeling M, Teljeur C, Feely J, Bennett K. Potentially
inappropriate prescribing and cost outcomes for older people: a national
population study. Br J Clin Pharmacol. 2010;69(5):543–52.
18. Bradley MC, Fahey T, Cahir C, Bennett K, O’Reilly D, Parsons C, et al.
Potentially inappropriate prescribing and cost outcomes for older people: a
cross-sectional study using the Northern Ireland Enhanced Prescribing
Database. Eur J Clin Pharmacol. 2012;68(10):1425–33.
19. Hamano J, Tokuda Y. Inappropriate prescribing among elderly home care
patients in Japan: prevalence and risk factors. J Prim Care Community
Health. 2014;5(2):90–6.
20. Kaufmann CP, Tremp R, Hersberger KE, Lampert ML. Inappropriate
prescribing: a systematic overview of published assessment tools. Eur J Cli
Pharmacol. 2013;70(1):1–11.
21. American Geriatrics Society. Updated Beers criteria for potentially
inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60
(4):616–31.
22. Gallagher P, Ryan C, Byrne S, Kennedy J, O’Mahony D. STOPP (Screening
Tool of Older Person’s Prescriptions) and START (Screening Tool to Alert
doctors to Right Treatment) Consensus validation. Int J Clin Pharmacol Ther.
2008;46(2):72–83.
23. Lam MPS, Cheung BMY. The use of STOPP/START criteria as a screening tool
for assessing the appropriateness of medications in the elderly population.
Expert Rev Clin Pharmacol. 2012;5(2):187–97.
24. Naugler CT, Brymer C, Stolee P, Arcese ZA. Development and validation of
an improving prescribing in the elderly tool. Can J Clin Pharmacol.
2000;7(2):103–7.
25. Curtain CM, Bindoff IK, Westbury JL, Peterson GM. A comparison of
prescribing criteria when applied to older community-based patients. Drugs
Aging. 2013;30(11):935–43.
26. Hill-Taylor B, Sketris I, Hayden J, Byrne S, O’Sullivan D, Christie R. Application
of the STOPP/START criteria: a systematic review of the prevalence of
potentially inappropriate prescribing in older adults, and evidence of
clinical, humanistic and economic impact. J Clin Pharm Ther.
2013;38(5):360–72.
27. Milos V, Rekman E, Bondesson Å, Eriksson T, Jakobsson U, Westerlund T,
et al. Improving the quality of pharmacotherapy in elderly primary care
patients through medication reviews: a randomised controlled study. Drugs
Aging. 2013;30(4):235–46.
28. Gillespie U, Alassaad A, Hammarlund-Udenaes M, Mörlin C, Henrohn D,
Bertilsson M, et al. Effects of pharmacists’ interventions on appropriateness
of prescribing and evaluation of the instruments' (MAI, STOPP and STARTs')
ability to predict hospitalization–analyses from a randomized controlled trial.
PLoS One. 2013;8(5):e62401.
29. Bergqvist M, Ulfvarson J, Karlsson EA. Nurse-led medication reviews and the
quality of drug treatment of elderly hospitalized patients. Eur J Clin
Pharmacol. 2009;65(11):1089–96.
30. Finkers F, Maring JG, Boersma F, Taxis K. A study of medication reviews to
identify drug-related problems of polypharmacy patients in the Dutch
nursing home setting. J Clin Pharm Ther. 2007;32(5):469–76.
31. Lenaghan E, Holland R, Brooks A. Home-based medication review in a high
risk elderly population in primary care–the POLYMED randomised controlled
trial. Age Ageing. 2007;36(3):292–7.
32. Garrido MM. Propensity scores: a practical method for assessing treatment
effects in pain and symptom management research. J Pain Symptom
Manage. 2014;48(4):711–8.
